One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1093/annonc/mdz394.039
Copy DOI
Export
Save
Share
Cite Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 Citations: 58 |  License type: publisher-specific-oa |
Affiliation: Northwestern University, Centre Hospitalier Universitaire de Besançon, Spanish National Cancer Research Centre, Centre Hospitalier de l’Université de Montréal, Tulane University, Radboud University Nijmegen, Radboud University Nijmegen Medical Centre, Peter MacCallum Cancer Centre, University of Utah, Huntsman Cancer Institute, AstraZeneca (United States), BC Cancer Agency, Institut Gustave Roussy, University of Paris-Sud, Institut Polytechnique de Paris, AstraZeneca (United Kingdom), Carolina Urologic Research Center, City Of Hope National Medical Center, MSD (United States), Institute of Cancer Research
LBA12_PR - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
